NEWS
New Diagnexia state-of-the- art Oxford histopathology lab
Diagnexia, the clinical digital pathology service of Deciphex, has opened a new, cutting-edge histopathology laboratory in Oxford. The advanced facility is set to significantly expand capacity for processing pathology samples in the UK, with the ability to handle up to 400,000 specimens annually, addressing the increasing demand for diagnostic services across the country. The Oxford laboratory will operate alongside Diagnexia’s existing digital pathology laboratory in Exeter. Together, these two facilities form a comprehensive service offering that combines physical
Roche’s advances in Alzheimer’s diagnostics
New data presented by Roche at the 17th Clinical Trials in Alzheimer’s Disease (CTAD) congress in Madrid, Spain highlight the potential of the Elecsys Amyloid Plasma Panel and Elecsys pTau181 for ruling out Alzheimer’s disease related amyloid pathology with very good accuracy.
In the largest worldwide clinical trial of its kind, the blood-based test showed very good accuracy in ruling out Alzheimer’s pathology in those being investigated for the disease, potentially avoiding the need for further invasive and unnecessary tests. In the prospective, multicentre
study, which included 492 patients across the US and Europe, the Roche Elecsys Amyloid Plasma Panel was able to rule out Alzheimer’s disease with a high negative predictive value (NPV) of 96.2% based on a 23.4% prevalence of amyloid positivity according to positron emission tomography (PET) scans, with 91.0% sensitivity and 69.8% specificity. The performance of the test was only minimally impacted by a patient’s age, sex, body mass index or impaired kidney function. Roche’s pTau181 biomarker performed similarly as a standalone assay. In addition to data on the Elecsys Amyloid Plasma Panel and pTau181, Roche also presented data for its Elecsys pTau 217 assay which is currently in development and also received FDA Breakthrough Device Designation earlier this year.
WWW.PATHOLOGYINPRACTICE.COM DECEMBER 2024 11
bioMérieux and St James’s Hospital in Ireland are proud to announce the world-first Centre of Reference partnership, providing innovative data & IT solutions to help combat antimicrobial resistance and aid in management of sepsis
For more information visit:
https://go.biomerieux.com/ODOT-uk
sample processing with state-of-the-art digital pathology workflows, providing faster, more efficient diagnostic solutions to hospitals and healthcare providers. “The opening of this facility marks a significant step forward in our commitment to addressing the critical needs of the UK’s healthcare system,” said Donal O’Shea, CEO of Diagnexia. “This new laboratory will allow us to deliver high-quality, responsive pathology services, supporting the NHS in managing growing diagnostic workloads and ultimately improving patient outcomes.” The facility is working towards securing
UKAS accreditation to further strengthen its support for the NHS, ensuring that Diagnexia continues to meet the needs of UK hospitals and healthcare providers. In addition to supporting NHS pathology services, the Oxford laboratory is set to expand Diagnexia’s capabilities in clinical trial services over the next 12 months. The site will play a key role in advancing medical research by offering specialised histopathology services for pharmaceutical companies and clinical trial sponsors.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
